Voltron Therapeutics, Inc. has signed a new Sponsored Research Agreement with the Vaccine and Immunotherapy Center at Massachusetts General Hospital, Harvard Medical School to initiate a pre-clinical immuno-oncology trial targeting prostate stem cell antigen in prostate, renal cell and urothelial cancers, adding important potential indications to its growing pipeline.

The platform will be used to sequence genomic information from a patient’s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.

FUJIFILM Irvine Scientific, Inc. has announced the launch of its BalanCD HEK293 Viral Feed.

Particle Works continues to pave the way for particle perfection with the highly anticipated launch of its second revolutionary platform, the Automated Library Synthesis (ALiS) System.

This year, the Biochemical Analytics Prize, endowed with 50,000 euros, will be
awarded to biochemistry professor, Dr Kai Simons and analytical chemist, Dr
Andrej Shevchenko, as well as to Professor Andreas Greinacher, a transfusion
medicine physician.

The Dynabeads™ Streptavidin for in vitro transcription and Dynabeads Carboxylic Acid for RNA purification solutions support scalable GMP-grade synthesis and purification of mRNA for vaccine development and manufacturing.

Peli BioThermal announces its newest reusable, flexible temperature-controlled shipping solution.

Voltron Therapeutics, Inc. has announced that data from the previously announced Study ‘098 demonstrated clear Proof-of Concept for VTX-067 in the treatment of HPV-related cancers.

Vaccizone has selected Exothera S.A. to fast-track process development of its SARS-CoV-2 vaccine for European clinical trials.

Lucius Partners, LLC has reported that its portfolio company, Voltron Therapeutics, Inc., had announced the initiation of a preclinical study of its novel vaccine candidate VTX-067 in an immune-oncology model.